ELAVL1 and prostate cancer: Prostate cancer-derived TDEVs contain circFMN2, which, upon binding to HuR, reduces the HuR-KLF2 interaction, inhibits KLF2 expression, and subsequently decreases RNF128 transcription, collectively promoting tumor cell proliferation, invasion, and migration (Huang et al., 2023).